Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients
NCT ID: NCT00780429
Last Updated: 2008-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
54 participants
OBSERVATIONAL
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: to investigate whether long-term MMF therapy alters IMPDH biological activity and if there are any correlations with the risk of AR.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)
NCT01822483
MPA Pharmacokinetics in Renal Transplantation
NCT01892761
Pilot Trial for Implementation of a MPA PK Monitoring Strategy
NCT00187915
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant
NCT00171379
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus
NCT00171392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
MMF+cyclosporine
No interventions assigned to this group
2
MMF+tacrolimus
No interventions assigned to this group
3
MMF+sirolimus
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age range: 18-70
* Patients taking MMF
* Able to understand and sign an informed consent
Exclusion Criteria
* Systemic infections or other that may affect MMF absorption
* Pregnancy/breastfeeding
* (History of) cancer
* Drug abuse, psychiatric conditions
* Already enrolled in other clinical trials or participation ended less than one month earlier
* Known sensitivity to polysorbate 80 or MMF
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
IRCCS Fondazione Policlinico San Matteo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Fondazione Policlinico San Matteo
Pavia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06/2006/REVO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.